Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
- Pierre-Simon Bellaye1,2,*,
- Toyoshi Yanagihara1,*,
- Elise Granton1,
- Seidai Sato1,3,
- Chiko Shimbori1,
- Chandak Upagupta1,
- Jewel Imani1,
- Nathan Hambly1,
- Kjetil Ask1,
- Jack Gauldie1,
- Marc Iglarz4 and
- Martin Kolb1
- 1Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
- 2Centre George-François Leclerc (CGFL), plateforme d'imagerie et radiothérapie préclinique, Dijon, France
- 3Dept of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
- 4Actelion Pharmaceuticals Ltd. - Allschwil, Switzerland
- Martin Kolb E-mail: kolbm{at}mcmaster.ca
* These authors contributed equally to this work
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Bellaye has nothing to disclose.
Conflict of interest: Dr. Yanagihara has nothing to disclose.
Conflict of interest: Dr. Granton has nothing to disclose.
Conflict of interest: Dr. Sato has nothing to disclose.
Conflict of interest: Dr. Shimbori has nothing to disclose.
Conflict of interest: Dr. Upagupta has nothing to disclose.
Conflict of interest: Dr. Imani has nothing to disclose.
Conflict of interest: Dr. Hambly has nothing to disclose.
Conflict of interest: Dr. Ask has nothing to disclose.
Conflict of interest: Dr. Gauldie has nothing to disclose.
Conflict of interest: Dr. Iglarz reports other from Actelion Pharmaceuticals Ltd., outside the submitted work; .
Conflict of interest: Dr. Kolb reports grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, grants and personal fees from GSK, grants and personal fees from Gilead, grants from Actelion, grants from Respivert, personal fees from Astra Zeneca, grants and personal fees from Prometic, personal fees from Genoa, grants and personal fees from Alkermes, grants from Synairgen, outside the submitted work; .
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018